Novartis AG - ADR (NVS) | Finance information

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to

Market

Industry

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$184 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt.	$195 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	$3.33 (4.34%)
1 Year Return Profit or loss of share price change plus dividend yield.	+0.6%
52-Week High Highest share price in the last 52 weeks.	$94.26
52-Week Low Lowest share price in the last 52 weeks.	$74.09
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return.	0.38
Outstanding Shares The number of shares the company has issued and are held by stockholders.	2.4 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days.	2.88 Million

Valuation

Compare to

Market

Industry

P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	8.01
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	-19.3
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value.	$10.25
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	3.62
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	2.92
Enterprise Value to Revenue Enterprise value divided by revenue	3.7
Enterprise Value to EBIT Enterprise Value divided by EBIT	7.03
Total Debt to Enterprise Value Total debt divided by enterprise value	0.16
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.49

Profitability

Compare to

Market

Industry

Revenue Revenue is the sum of all cash flow into the company.	$52.8 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services.	$37.3 Billion
EBIT Earnings before tax and interest payments.	$27.8 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue.	$23 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	43.54%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-41.5%
Return on Equity Equity divided by market cap.	36.52%
Return on Assets Indicates a company's profitability in relation to its total assets.	18.70%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	29.19%

Insider trades

Q1 2022 Q2 2022 Q3 2022 Q4 2022

About Novartis AG - ADR

CEO: Vasant Narasimhan

Industry: Pharmaceuticals: Major

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Similar stocks

Glaxosmithkline plc - ADR

Teva- Pharmaceutical Industries Ltd. - ADR

Abbott Laboratories

Bayer AG - ADR

Astrazeneca plc - ADR

News

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

Novartis recently announced encouraging results from its clinical trial of its Prolia biosimilar.

The Motley Fool, 1 day ago

Supreme Court grants Novartis request to halt Gilenya patent cancellation

The Swiss company said it would suffer irreparable harm if generics for the multiple sclerosis drug were allowed to enter the market before the higher court ...

BioPharma Dive, 4 days ago

Novartis (NYSE: NVS) Wins Reprieve From U.S. Supreme Court Regarding Gilenya

On Thursday, Novartis (NYSE: NVS) won a reprieve from the U.S. Supreme Court after it put on hold the cancellation of some of Novartis'' patents on the dosag...

TipRanks, 4 days ago